Add-on to Cognitive, Event-Related Potentials (ERP) and Electroencephalogram (EEG) Asymmetry in Affective Disorders

New York State Psychiatric Institute

Status and phase: Withdrawn; Phase 4

Conditions: Depressive Illness

Treatments: Drug: bupropion; Drug: citalopram

Study type: Interventional

Funder types: Other

Identifiers

NCT03278938

#5723

Details and patient eligibility

About

Depressed patients unremitted after monotherapy with citalopram or bupropion will remit following six weeks treatment with the combination of citalopram and bupropion.

Full description

Participants in another study who did not remit during 12 weeks treatment with citalopram (to 40 mg/d) or bupropion (to 450 mg/d) will have citalopram (to 40 mg/d) or bupropion (to 450 mg/d) added for six weeks.

Sex: All

Ages: 18 to 66 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• non-remission in Protocol #6559R
• age 18-66
• signs informed consent
• physically healthy

Exclusion criteria

• bipolar disorder
• history of psychosis
• history of anorexia nervosa or bulimia
• history of seizure disorder, significant brain trauma or other medical reason to suspect increased seizure risk

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

0 participants in 2 patient groups

bupropion added to citalopram

Active Comparator group

Description:

patients who did not remit with citalopram will continue at the same dose and have bupropion added

Treatment:

Drug: citalopram

Drug: bupropion

citalopram added to bupropion

Active Comparator group

Description:

Patients who did not remit with bupropion will have bupropion continued at the same dose and citalopram will be added

Treatment:

Drug: citalopram

Drug: bupropion